🟠 Two Phase 3 trials (VX20-121-102 and VX20-121-103) enrolled 971 patients (median age ~32 years) to evaluate lung function and sweat chloride improvements over 52 weeks. 
#CRISPR #biotech $VRTX $NTLA $PRME $EDIT @FDA